VEXAS Syndrome

The most efficacious targeted therapies for VEXAS syndrome are Janus kinase inhibitors and interleukin-6 inhibitors, while IL-1 and TNF blockers are less effective, according to data published in the Annals of the Rheumatic Diseases.

Skin manifestations are common in VEXAS syndrome and evaluating their presentations can assist in genotyping the disease and possibly lead to better diagnoses, according to a study.

SAN DIEGO — Janus kinase and interleukin-6 inhibitors are superior to other targeted agents as a first-line therapy for VEXAS syndrome, according to data presented at ACR Convergence 2023.

VEXAS syndrome is “more common than expected” in both men and women, with one in 13,591 individuals demonstrating a UBA1 disease-causing variant, according to data published in JAMA.